Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 3:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Dry Eye Disease Clear all
Completed Not applicable Interventional Results available

Acute Comfort and Blur of Systane Ultra and Systane

NCT00748865
View directory record Official record
Conditions
Dry Eye
Interventions
Systane Ultra Lubricant Eye Drops, Systane Lubricant Eye Drops
Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Feb 1, 2012 · Synced Jul 21, 2026, 3:25 PM EDT
Terminated Phase 2 Interventional Results available

Evaluation of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease

NCT02831387
View directory record Official record
Conditions
Dry Eye Disease
Interventions
P-321 Ophthalmic Solution, P-321 Ophthalmic Solution placebo
Drug
Lead sponsor
Parion Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Artesia, California • Kansas City, Missouri • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Jul 21, 2026, 3:25 PM EDT
Completed Phase 2 Interventional Results available

Phase 2, Multi-center, Randomized, Double- Masked and Placebo-Controlled Study of YP-P10 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (ICECAP 1)

NCT05467293
View directory record Official record
Conditions
Dry Eye
Interventions
0.3% YP-P10 Ophthalmic Solution, 1% YP-P10 Ophthalmic Solution, YP-P10 Placebo Ophthalmic Solution (vehicle)
Drug
Lead sponsor
Yuyu Pharma, Inc.
Industry
Eligibility
Not listed
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
7
States / cities
Phoenix, Arizona • Newport Beach, California • Colorado Springs, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Jul 21, 2026, 3:25 PM EDT
Active, not recruiting Phase 3 Interventional

Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

NCT05349214
View directory record Official record
Conditions
Sjogren Syndrome
Interventions
VAY736, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
23
States / cities
Fullerton, California • La Palma, California • Brandon, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 21, 2026, 3:25 PM EDT
Completed No phase listed Observational Results available

Effects of Cataract Extraction Surgery and Limbal Relaxing Incision on Corneal Sensation and Dry Eye

NCT01161771
View directory record Official record
Conditions
Dry Eye
Interventions
Cataract Surgery and Limbal relaxing incision
Procedure
Lead sponsor
Allergan
Industry
Eligibility
50 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Long Island City, New York
Source: ClinicalTrials.gov public record
Updated Jul 25, 2012 · Synced Jul 21, 2026, 3:25 PM EDT
Completed Early Phase 1 Interventional

The Effects and Safety of 5% Lifitegrast Ophthalmic Solution in Subjects With Dry Eye Disease in Ocular Graft-versus-Host Disease

NCT04792580
View directory record Official record
Conditions
Graft-versus-host-disease, Ocular Graft-versus-host Disease
Interventions
Lifitegrast 5% Ophthalmic Solution, Placebo
Drug
Lead sponsor
Richard W Yee, MD
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Bellaire, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2024 · Synced Jul 21, 2026, 3:25 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis

NCT01456780
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Posterior Blepharitis
Interventions
Loteprednol/tobramycin, Loteprednol, B+L Advanced Eye Relief Lubricant Drop
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Jul 21, 2026, 3:25 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Diurnal Variation of Tear Meniscus and Tear Osmolarity

NCT01206244
View directory record Official record
Conditions
Dry Eye
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 12, 2013 · Synced Jul 21, 2026, 3:25 PM EDT
Terminated Phase 4 Interventional Results available

Effects of Supplementation With PUFAs and Antioxidants for Contact Lens Discomfort

NCT04163328
View directory record Official record
Conditions
Dry Eye, Contact Lens Complication
Interventions
HydroEye®
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Jul 21, 2026, 3:25 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy

NCT06018558
View directory record Official record
Conditions
Geographic Atrophy
Interventions
OCU410
Genetic
Lead sponsor
Ocugen
Industry
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
12
States / cities
Phoenix, Arizona • Coral Springs, Florida • Carmel, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Jul 21, 2026, 3:25 PM EDT
Recruiting Phase 4 Interventional

SYSTANE® PRO vs. MIEBO™ in Dry Eye Disease

NCT07243275
View directory record Official record
Conditions
Dry Eye Disease (DED)
Interventions
SYSTANE® PRO, MIEBO™ (Perfluorohexyloctane, PFHO)
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
4
States / cities
Newport Beach, California • Bloomington, Indiana • Pittsburg, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jul 21, 2026, 3:25 PM EDT
Not yet recruiting No phase listed Observational

Rehabilitating Vision Loss in Veterans With Age-Related Macular Degeneration

NCT05780931
View directory record Official record
Conditions
Age-related Macular Degeneration (AMD)
Interventions
Study-specific rehabilitation (SSR) procedures
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 21, 2026, 3:25 PM EDT
Recruiting No phase listed Observational

Real-World Assessment of VEVYE® for Short-Term Symptom and Sign Improvement of Dry Eye Disease in a Neuro-Ophthalmology Clinic: A 6-Month Prospective Observational Study

NCT07566975
View directory record Official record
Conditions
Dry Eye
Interventions
Cyclosporine ophthalmic solution 0.1%
Other
Lead sponsor
Neuro-Ophthalmology of Texas
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jul 21, 2026, 3:25 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Carbidopa-Levodopa in Dry AMD With Geographic Atrophy

NCT03451500
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
carbidopa-levodopa
Drug
Lead sponsor
Snyder, Robert W., M.D., Ph.D., P.C.
Individual
Eligibility
50 Years to 85 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Jul 21, 2026, 3:25 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of KPI-121 in Subjects With DED

NCT03616899
View directory record Official record
Conditions
Kerato Conjunctivitis Sicca
Interventions
KPI-121 Ophthalmic Suspension, Vehicle
Drug
Lead sponsor
Kala Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
901 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
81
States / cities
Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Jul 21, 2026, 3:25 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

An Open-Label, Multi-Center, Clinical Study Evaluating the Effect of the NDE L68 StableFit® Punctal Plug on the Tear Lake

NCT04280653
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
NDE L68 StableFit® Punctal Plug
Device
Lead sponsor
Mati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
2
States / cities
Edgewood, Kentucky • Garden City, New York
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Jul 21, 2026, 3:25 PM EDT
Withdrawn Phase 4 Interventional

Use of 5.0% Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Disease in Contact Lens Wearers

NCT03431272
View directory record Official record
Conditions
Contact Lens Dry Eye
Interventions
Lifitegrast
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Jul 21, 2026, 3:25 PM EDT
Completed No phase listed Observational

A Retrospective Analysis of Restasis® Benefits in Dry Eye Contact Lens Patients

NCT02522312
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
No Intervention
Other
Lead sponsor
Hazleton Eye Specialists
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Hazleton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 2, 2016 · Synced Jul 21, 2026, 3:25 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Safety and Efficacy of BOL-303242-X Ophthalmic Suspension in Dry Eye Syndrome

NCT01163643
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
0.3% BOL-303242-X ophthalmic suspension, 2% BOL-303242-X ophthalmic suspension, Placebo Comparator: Vehicle, 1% BOL-303242-X ophthalmic suspension, 2% BOL-303242-X ophthalmic suspension AM, 2% BOL-303242-X ophthalmic suspension PM
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Jul 21, 2026, 3:25 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Subjects With Dry Eye - Effects on Central Cornea

NCT01057147
View directory record Official record
Conditions
Keratoconjunctivitis Sicca, Dry Eye
Interventions
rebamipide 2% ophthalmic suspension, placebo eye drops
Drug
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
19
States / cities
Mesa, Arizona • Phoenix, Arizona • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2012 · Synced Jul 21, 2026, 3:25 PM EDT
Completed Phase 2Phase 3 Interventional

Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome

NCT00198536
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Ecabet 2.83%, Ecabet 3.70%, Vehicle
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
3
States / cities
Lewiston, Maine • Andover, Massachusetts • Dover, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 13, 2013 · Synced Jul 21, 2026, 3:25 PM EDT
Completed Phase 2Phase 3 Interventional Results available

The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease

NCT04674358
View directory record Official record
Conditions
Dry Eye, Dry Eye Syndromes
Interventions
Reproxalap Ophthalmic Solution (0.25%), Vehicle Opthalmic Solution
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Jul 21, 2026, 3:25 PM EDT
Withdrawn Not applicable Interventional

Study of Platelet Rich Plasma Drops to Moderate Clinically Significant Dry Eye

NCT05121493
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Platelet Poor Plasma Tear Drops, Platelet Rich Plasma Tear Drops
Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 21, 2026, 3:25 PM EDT
Completed Not applicable Interventional

The Effect of Punctal Plugs on Ocular Surface After Povidone-Iodine Preparation of Intravitreal Injection

NCT03945071
View directory record Official record
Conditions
Dry Eye Syndromes, Dry Eye, Ocular Surface Disease
Interventions
Punctal plug
Device
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 6, 2023 · Synced Jul 21, 2026, 3:25 PM EDT